3 results
Approved WMORecruiting
To determine non inferiority of two doses of BI 10773 (10 mg/daily and 25 mg/daily) compared to placebo with respect to first occurrence of any of the adjudicated components of the primary composite Major Adverse Cardiovascular Event endpoint (…
Approved WMOCompleted
Primary Objective•*To evaluate the relative oral bioavailability of SMV, ODV, and AL-335 when administered as different concept fixed-dose combination (FDC) formulations compared to the single agents when administered together, all under fed…
Approved WMOCompleted
The objective of the study is to demonstrate the safety and performance of the Adagio Cryoablation System in patients with paroxysmale (PAF), persistent or Long-Standing Persistent Atrial Fibrillation.